Combined liver transplantation and sleeve gastrectomy: Report of a brief‐interval staged approach

Nabil Tariq, Ashish Saharia, Ugoeze Nwokedi, Mark J. Hobeika, Constance M. Mobley, David Hsu, Lucy M. Potter, Linda W. Moore, Ahmed Elaileh, Vadim Sherman, R. Mark Ghobrial – 16 August 2022 – Pretransplantation bariatric surgery in patients with high Model for End‐Stage Liver Disease (MELD) score is fraught with risks. Bariatric surgery after liver transplantation (LT) may be complicated by surgical adhesions but could have advantages if performed at the time of transplantation. We investigated a method of brief‐interval staging combining LT and sleeve gastrectomy (SG).

Mitochondrial stress in advanced fibrosis and cirrhosis associated with chronic hepatitis B, chronic hepatitis C, or nonalcoholic steatohepatitis

Dimitri Loureiro, Issam Tout, Stéphanie Narguet, Cheikh Mohamed Bed, Morgane Roinard, Ahmad Sleiman, Nathalie Boyer, Nathalie Pons‐Kerjean, Corinne Castelnau, Nathalie Giuly, Dorothy Tonui, Vassili Soumelis, Jamel El Benna, Patrick Soussan, Richard Moreau, Valérie Paradis, Abdellah Mansouri, Tarik Asselah – 15 August 2022

Development and validation of the Cirrhotic Ascites Severity model—A patient‐reported outcome‐based model to predict 1‐year mortality

Rasmus Hvidbjerg Gantzel, Niels Kristian Aagaard, Hendrik Vilstrup, Hugh Watson, Henning Grønbæk, Peter Jepsen – 15 August 2022 – Ascites formation is a sign of decompensation of cirrhosis and heralds a poor prognosis. The widely used standard binary classification of ascites as diuretic‐responsive or refractory does not cover the spectrum of ascites and has limited prognostic information. We developed the Cirrhotic Ascites Severity (CIRAS) model to predict 1‐year mortality among 465 patients randomized to placebo in the satavaptan trials investigating treatment of cirrhotic ascites.

Clinical trials in hepatitis D virus: Measuring success

Ben L. Da – 14 August 2022 – Chronic hepatitis D infection results in the most severe form of chronic viral hepatitis but currently lacks effective treatment options. Therapy with pegylated interferon alpha is recommended for finite treatment duration by major liver societies. Still, it is plagued by low rates of sustained virologic response (SVR) and frequent relapses even if SVR is achieved. Recently, a wave of investigational therapies has come under evaluation, including bulevirtide, lonafarnib, pegylated interferon lambda, and REP‐2139 creating excitement with this viral infection.

Subscribe to